Literature DB >> 11489245

Allogeneic stem-cell transplantation in renal-cell carcinoma.

B M Hayes-Lattin1, R T Maziarz, T M Beer.   

Abstract

Metastatic renal-cell carcinoma (RCC) remains resistant to nearly all standard cytotoxic therapies, but immune-based cytokine therapies benefit a small minority of patients with advanced RCC. Nonmyeloablative allogeneic stem-cell transplantation is a novel approach to harnessing the immune system to combat this cancer. The strategy relies on a T-cell graft-versus-malignancy effect mediated by donor T cells. Preliminary work in using nonmyeloablative allogeneic stem-cell transplant in RCC has identified a graft-versus-RCC effect and yielded encouraging clinical responses.

Entities:  

Mesh：

Year:  2001        PMID： 11489245     DOI： 10.1007/s11912-001-0030-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  45 in total

Review 1.  Interferon in metastatic renal cell carcinoma.

Authors:  S D Fosså
Journal:  Semin Oncol       Date:  2000-04       Impact factor: 4.929

Review 2.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

3.  Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas.

Authors:  N Guerra; M Guillard; E Angevin; H Echchakir; B Escudier; A Moretta; S Chouaib; A Caignard
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

4.  Graft-versus-myeloma effect in two cases.

Authors:  L F Verdonck; H M Lokhorst; A W Dekker; H K Nieuwenhuis; E J Petersen
Journal:  Lancet       Date:  1996-03-23       Impact factor: 79.321

5.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

6.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors:  R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

Review 7.  Adoptive cellular therapy.

Authors:  D M Hoffman; B J Gitlitz; A Belldegrun; R A Figlin
Journal:  Semin Oncol       Date:  2000-04       Impact factor: 4.929

8.  CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells.

Authors:  D D Schoof; Y Terashima; G E Peoples; P S Goedegebuure; J V Andrews; J P Richie; T J Eberlein
Journal:  Cell Immunol       Date:  1993-08       Impact factor: 4.868

9.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

Authors:  H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

10.  Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.

Authors:  S Slavin; E Naparstek; A Nagler; A Ackerstein; S Samuel; J Kapelushnik; C Brautbar; R Or
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.